@dido2 The Tevogen Bio’s TVGN‑489, an allogeneic cytotoxic T‑lymphocyte therapy targets SARS‑CoV‑2 antigens broadly (including but not limited to spike), has been studied as a therapeutic avenue for persistent viral reservoirs. (reservoirs throughout the body but on the brain and the gut).

Have you heard about the SPEAR group? This involves monoclonal therapy. https://investors.invivyd.com/news-releases/news-release-details/invivyd-and-leading-researchers-form-spear-spike-protein